The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet
Pharmaceutical Commerce
JULY 16, 2025
1 In response to this immense demand, coupled with high costs and accessibility issues, compounded alternatives have emerged as a seemingly pragmatic solution. However, these compounded GLP-1s are creating a significant, often underestimated, legal, reputational, and financial minefield for startups and the broader life sciences industry.
Let's personalize your content